JP2020514415A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514415A5
JP2020514415A5 JP2019571803A JP2019571803A JP2020514415A5 JP 2020514415 A5 JP2020514415 A5 JP 2020514415A5 JP 2019571803 A JP2019571803 A JP 2019571803A JP 2019571803 A JP2019571803 A JP 2019571803A JP 2020514415 A5 JP2020514415 A5 JP 2020514415A5
Authority
JP
Japan
Prior art keywords
alkyl
group
nitrogen
independently selected
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019571803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514415A (ja
JP7239497B2 (ja
Filing date
Publication date
Priority claimed from GB1703979.3A external-priority patent/GB2561540A/en
Application filed filed Critical
Publication of JP2020514415A publication Critical patent/JP2020514415A/ja
Publication of JP2020514415A5 publication Critical patent/JP2020514415A5/ja
Priority to JP2022188339A priority Critical patent/JP2023025110A/ja
Application granted granted Critical
Publication of JP7239497B2 publication Critical patent/JP7239497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019571803A 2017-03-13 2018-03-12 化合物 Active JP7239497B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022188339A JP2023025110A (ja) 2017-03-13 2022-11-25 化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1703979.3A GB2561540A (en) 2017-03-13 2017-03-13 Chemical compounds
GB1703979.3 2017-03-13
PCT/GB2018/050623 WO2018167468A1 (en) 2017-03-13 2018-03-12 Chemical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022188339A Division JP2023025110A (ja) 2017-03-13 2022-11-25 化合物

Publications (3)

Publication Number Publication Date
JP2020514415A JP2020514415A (ja) 2020-05-21
JP2020514415A5 true JP2020514415A5 (https=) 2021-04-22
JP7239497B2 JP7239497B2 (ja) 2023-03-14

Family

ID=58605540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019571803A Active JP7239497B2 (ja) 2017-03-13 2018-03-12 化合物
JP2022188339A Pending JP2023025110A (ja) 2017-03-13 2022-11-25 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022188339A Pending JP2023025110A (ja) 2017-03-13 2022-11-25 化合物

Country Status (15)

Country Link
US (1) US11345669B2 (https=)
EP (1) EP3596052B1 (https=)
JP (2) JP7239497B2 (https=)
KR (1) KR102581620B1 (https=)
CN (1) CN110869352B (https=)
AU (1) AU2018234278B2 (https=)
BR (1) BR112019018854A2 (https=)
CA (1) CA3056302A1 (https=)
EA (1) EA201992152A1 (https=)
ES (1) ES2928447T3 (https=)
GB (1) GB2561540A (https=)
IL (1) IL269204B (https=)
SG (1) SG11201908228TA (https=)
WO (1) WO2018167468A1 (https=)
ZA (1) ZA201906035B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
BR112021014389A2 (pt) * 2019-01-25 2021-09-28 NodThera Limited Derivados de carbamato e usos dos mesmos
AU2021291065B2 (en) * 2020-06-19 2025-06-26 Ac Immune Sa Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway
EP3984535A1 (en) * 2020-10-16 2022-04-20 Albert-Ludwigs-Universität Freiburg Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
CN114874135B (zh) * 2021-02-05 2024-03-22 西南医科大学 一类抗乳腺癌的小分子化合物及其制备方法
CN116143753B (zh) * 2021-08-26 2025-07-08 瑞石生物医药有限公司 Nlrp3抑制剂化合物
CN118541366A (zh) * 2021-12-22 2024-08-23 Ac免疫有限公司 二氢噁唑衍生物化合物
CN116496255B (zh) * 2022-01-27 2026-01-30 杭州邦顺制药股份有限公司 Nlrp3抑制剂
CN115974745B (zh) * 2022-12-27 2025-06-03 瑞石生物医药有限公司 一类含引达省的化合物及其医药用途
CN116640091A (zh) * 2023-05-25 2023-08-25 上海吉奉生物科技有限公司 一种Boc-3-(3-吡啶基)- L -丙氨酸的合成方法
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
GB202404002D0 (en) 2024-03-20 2024-05-01 Univ Bristol Antimicrobial compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG23537A3 (bg) * 1973-05-22 1977-09-15 Philargo S.A. Средство за регулиране растежа на растенията
GB1479544A (en) * 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
DE3522938A1 (de) * 1985-06-27 1987-01-08 Bayer Ag Leistungsfoerdernde mittel
EP0920424B1 (en) 1996-08-22 2005-11-30 Warner-Lambert Company Llc Non-peptide bombesin receptor antagonists
EP1433779A1 (en) 2002-12-23 2004-06-30 Jerini AG Use of nitriles as inhibitors of non-proteolytic enzymes
US6846836B2 (en) * 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP5947724B2 (ja) * 2009-12-21 2016-07-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル シクロフィリンの新しいインヒビター及びその使用
GB201018171D0 (en) 2010-10-28 2010-12-08 Givaudan Sa Organic compounds
EP2660096B1 (en) 2010-12-28 2018-10-10 Kawasaki Jukogyo Kabushiki Kaisha Acceleration control system for electric vehicle
EP2734240B1 (en) 2011-07-18 2018-03-21 University Of Kentucky Research Foundation Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
KR102223384B1 (ko) * 2013-03-06 2021-03-05 알러간, 인코포레이티드 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도
SI3259253T1 (sl) * 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome

Similar Documents

Publication Publication Date Title
JP2020514415A5 (https=)
US20240293521A1 (en) Combination use of wt1 antigen peptide and immunomodulator
ES3036330T3 (en) Imidazopyridazines as modulators of il-17
US11957657B2 (en) Combination therapies using immuno-dash inhibitors and PGE2 antagonists
TWI664966B (zh) 治療性化合物
US9387231B2 (en) Compositions comprising a Brd4 antagonist and methods for the treatment of HIV
KR102630889B1 (ko) 키나제를 조절하는 화합물의 고형 형태
JP6496823B2 (ja) 新規置換インダゾール、その製造方法、前記新規置換インダゾールを含む医薬製剤、および薬剤を製造するための前記新規置換インダゾールの使用
TWI696611B (zh) 甘胺酸醯胺化合物的製造方法
CN109152771B (zh) 2-取代的吲唑用于治疗和预防自身免疫疾病的用途
PH12022550611A1 (en) Brd9 bifunctional degraders and their methods of use
BR122020006918B1 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
CN116096704A (zh) 用于治疗癌症的组合疗法
US20160287605A1 (en) Combination therapy
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
BR112018003212A2 (en) diacerein or analogues thereof to inhibit asc expression, nlrp3 expression and / or inflammasome nlrp3 complex formation
CN113348181A (zh) 包含sting激动剂的dc-sign抗体缀合物
BR112019021880A2 (pt) Terapia de combinação com conjugado anticorpo anti-axl-droga
JP2005538099A5 (https=)
EP3846803A2 (en) Macrocyclic compounds for the treatment of medical disorders
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
WO2018187698A2 (en) Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists
JP2022552975A (ja) 関節リウマチを予防及び/又は治療するためのニコチンアミドモノヌクレオチド(nmn)の使用、並びに対応する組成物
WO2022087719A1 (en) Methods of treating spondyloarthritis or symptoms thereof
US12171729B2 (en) Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors